<p>根据其最近向证券交易委员会（SEC）提交的 13F 文件，Exchange Traded Concepts LLC 在 2023 年第三季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）的股份增加了 34.7%。该公司在此期间购买了 1,369 股后，持有 5,309 股该生物制药公司的股票。Exchange Traded Concepts LLC 在再生元制药的持股在最近的报告期末价值为 2,985,000 美元。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p>其他几家对冲基金最近也买卖了该公司的股票。Activest Wealth Management 在第一季度将其在再生元制药的股份增加了 110.5%。Activest Wealth Management 现在拥有 40 股该生物制药公司的股票，价值 25,000 美元，此前在上个季度又购买了 21 股。沙特中央银行在第一季度购买了再生元制药的新股份，价值约 27,000 美元。Migdal Insurance &amp; Financial Holdings Ltd.在第二季度购买了再生元制药的新股份，价值约 31,000 美元。Traub Capital Management LLC 在第二季度购买了再生元制药的新股份，价值约 38,000 美元。最后，Berbice Capital Management LLC 在第二季度将其在再生元制药的持股增加了 300.0%。Berbice Capital Management LLC 现在拥有 80 股该生物制药公司的股票，价值 42,000 美元，此前在上个季度又购买了 60 股。机构投资者持有该公司 83.31% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票分析师最近对 REGN 股票发表了评论。Raymond James Financial 在 9 月 2 日的报告中将再生元制药的股票评级上调至 “适度买入”。Canaccord Genuity Group 在 12 月 4 日的报告中将再生元制药的股票目标价从 850.00 美元上调至 1,057.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 11 月 24 日的报告中开始覆盖再生元制药的股票。他们为该公司设定了 “买入” 评级和 798.00 美元的目标价。Wall Street Zen 在 12 月 20 日的研究报告中将再生元制药的评级从 “买入” 下调至 “持有”。最后，美国银行在 10 月 29 日的研究报告中将再生元制药的目标价从 543.00 美元上调至 627.00 美元，并给予该公司 “表现不佳” 评级。三位股票研究分析师对该股票给予了强烈买入评级，十五位给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，共识目标价为 779.45 美元。</p>
<ul>
<li>5 个值得关注的医疗保健股票，因行业轮动已全面展开</li>
</ul>
<p><strong>查看我们最新的 REGN 股票报告</strong></p>
<h2>再生元制药价格表现</h2>
<p>NASDAQ:REGN 在周五开盘价为 779.70 美元。该公司的市值为 819.5 亿美元，市盈率为 18.67，PEG 比率为 2.25，贝塔值为 0.37。该公司的债务与股本比率为 0.09，流动比率为 4.06，速动比率为 3.33。该公司的 50 日简单移动平均为 699.36 美元，200 日简单移动平均为 607.79 美元。再生元制药公司一年的最低价为 476.49 美元，最高价为 792.77 美元。</p>
<ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>再生元制药（NASDAQ:REGN - 获取免费报告）最近于 10 月 28 日发布了其财报。这家生物制药公司报告本季度每股收益为 11.83 美元，超出市场共识预期的 9.73 美元，超出幅度为 2.10 美元。该公司本季度的收入为 37.5 亿美元，而市场共识预期为 35.7 亿美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该公司本季度的收入较去年同期增长了 0.9%。在去年同期，该公司每股收益为 12.46 美元。股票分析师预测再生元制药公司本年度将发布 35.92 美元的每股收益。</p>
<h2>再生元制药分红公告</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 12 月 5 日支付。11 月 20 日的股东记录上发放了 0.88 美元的分红。这代表着每年 3.52 美元的分红和 0.5% 的分红收益率。除息日为 11 月 20 日。再生元制药的分红支付比率（DPR）为 8.43%。</p>
<h2>再生元制药的内部交易</h2>
<p>在其他再生元制药的新闻中，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股该公司的股票。这些股票以 651.43 美元的平均价格出售，总价值为 280,766.33 美元。交易完成后，该副总裁持有该公司 4,233 股股票，价值为 2,757,503.19 美元。这笔交易代表了他们持股的 9.24% 的减少。该交易在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股该公司的股票。这些股票以 654.27 美元的平均价格出售，总价值为 4,252,755.00 美元。交易完成后，该董事直接持有该公司 2,352 股股票，价值约为 1,538,843.04 美元。这代表了他们持股的 73.43% 的减少。该交易的 SEC 文件提供了更多信息。当前 7.02% 的股票由内部人士持有。</p>
<h2>关于再生元制药</h2>
<p>（免费报告）</p>
<p>再生元制药公司（Regeneron Pharmaceuticals, Inc.）纳斯达克代码：REGN，是一家成立于 1988 年，总部位于纽约塔里敦的美国生物技术公司。该公司专注于发现、开发、生产和商业化用于治疗严重医疗状况的药物。公司结合实验室研究、临床开发和内部生产，推进多个治疗领域的生物治疗管线。</p>
<p>再生元以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比再生元制药更好的股票</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的水晶金属性能超过硅达 100 倍</li>
<li>来自奇怪的新 “AI 燃料” 的 33000% 繁荣？</li>
</ul>
<p><strong>想看看其他对 REGN 感兴趣的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取再生元制药公司（NASDAQ:REGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于再生元制药吗？</h2>
<p>在考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而再生元制药并不在名单上。</p>
<p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>Exchange Traded Concepts LLC 在第三季度将其在再生元制药的持股增加了 34.7%，目前拥有 5,309 股，价值 2,985,000 美元。分析师的评级意见不一，普遍认为为 “适度买入”，目标价格为 779.45 美元。再生元报告第三季度每股收益为 11.83 美元，超出预期，收入为 37.5 亿美元。公司宣布季度股息为每股 0.88 美元</p>

<p>Exchange Traded Concepts LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 34.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,309 shares of the biopharmaceutical company's stock after purchasing an additional 1,369 shares during the period. Exchange Traded Concepts LLC's holdings in Regeneron Pharmaceuticals were worth $2,985,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据其最近向证券交易委员会（SEC）提交的 13F 文件，Exchange Traded Concepts LLC 在 2023 年第三季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）的股份增加了 34.7%。该公司在此期间购买了 1,369 股后，持有 5,309 股该生物制药公司的股票。Exchange Traded Concepts LLC 在再生元制药的持股在最近的报告期末价值为 2,985,000 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of the company. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 21 shares in the last quarter. Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $27,000. Migdal Insurance &amp; Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $31,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, Berbice Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 60 shares in the last quarter. Institutional investors own 83.31% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也买卖了该公司的股票。Activest Wealth Management 在第一季度将其在再生元制药的股份增加了 110.5%。Activest Wealth Management 现在拥有 40 股该生物制药公司的股票，价值 25,000 美元，此前在上个季度又购买了 21 股。沙特中央银行在第一季度购买了再生元制药的新股份，价值约 27,000 美元。Migdal Insurance &amp; Financial Holdings Ltd.在第二季度购买了再生元制药的新股份，价值约 31,000 美元。Traub Capital Management LLC 在第二季度购买了再生元制药的新股份，价值约 38,000 美元。最后，Berbice Capital Management LLC 在第二季度将其在再生元制药的持股增加了 300.0%。Berbice Capital Management LLC 现在拥有 80 股该生物制药公司的股票，价值 42,000 美元，此前在上个季度又购买了 60 股。机构投资者持有该公司 83.31% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities analysts have recently commented on REGN shares. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a &#34;moderate buy&#34; rating in a report on Tuesday, September 2nd. Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 4th. Truist Financial initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $798.00 price objective for the company. Wall Street Zen lowered Regeneron Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, December 20th. Finally, Bank of America increased their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an &#34;underperform&#34; rating in a research note on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $779.45.</p>
<div class="lb-trans"><p>几位股票分析师最近对 REGN 股票发表了评论。Raymond James Financial 在 9 月 2 日的报告中将再生元制药的股票评级上调至 “适度买入”。Canaccord Genuity Group 在 12 月 4 日的报告中将再生元制药的股票目标价从 850.00 美元上调至 1,057.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 11 月 24 日的报告中开始覆盖再生元制药的股票。他们为该公司设定了 “买入” 评级和 798.00 美元的目标价。Wall Street Zen 在 12 月 20 日的研究报告中将再生元制药的评级从 “买入” 下调至 “持有”。最后，美国银行在 10 月 29 日的研究报告中将再生元制药的目标价从 543.00 美元上调至 627.00 美元，并给予该公司 “表现不佳” 评级。三位股票研究分析师对该股票给予了强烈买入评级，十五位给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，共识目标价为 779.45 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个值得关注的医疗保健股票，因行业轮动已全面展开</li>
</ul>
</div><p><strong>View Our Latest Stock Report on REGN</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 REGN 股票报告</strong></p>
</div><h2>Regeneron Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>再生元制药价格表现</h2>
</div><p>NASDAQ:REGN opened at $779.70 on Friday. The firm has a market capitalization of $81.95 billion, a price-to-earnings ratio of 18.67, a PEG ratio of 2.25 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The business has a 50 day simple moving average of $699.36 and a 200-day simple moving average of $607.79. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $792.77.</p>
<div class="lb-trans"><p>NASDAQ:REGN 在周五开盘价为 779.70 美元。该公司的市值为 819.5 亿美元，市盈率为 18.67，PEG 比率为 2.25，贝塔值为 0.37。该公司的债务与股本比率为 0.09，流动比率为 4.06，速动比率为 3.33。该公司的 50 日简单移动平均为 699.36 美元，200 日简单移动平均为 607.79 美元。再生元制药公司一年的最低价为 476.49 美元，最高价为 792.77 美元。</p>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company's revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.46 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）最近于 10 月 28 日发布了其财报。这家生物制药公司报告本季度每股收益为 11.83 美元，超出市场共识预期的 9.73 美元，超出幅度为 2.10 美元。该公司本季度的收入为 37.5 亿美元，而市场共识预期为 35.7 亿美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该公司本季度的收入较去年同期增长了 0.9%。在去年同期，该公司每股收益为 12.46 美元。股票分析师预测再生元制药公司本年度将发布 35.92 美元的每股收益。</p>
</div><h2>Regeneron Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>再生元制药分红公告</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.43%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 12 月 5 日支付。11 月 20 日的股东记录上发放了 0.88 美元的分红。这代表着每年 3.52 美元的分红和 0.5% 的分红收益率。除息日为 11 月 20 日。再生元制药的分红支付比率（DPR）为 8.43%。</p>
</div><h2>Insider Transactions at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>再生元制药的内部交易</h2>
</div><p>In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm's stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company's stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the company's stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他再生元制药的新闻中，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股该公司的股票。这些股票以 651.43 美元的平均价格出售，总价值为 280,766.33 美元。交易完成后，该副总裁持有该公司 4,233 股股票，价值为 2,757,503.19 美元。这笔交易代表了他们持股的 9.24% 的减少。该交易在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股该公司的股票。这些股票以 654.27 美元的平均价格出售，总价值为 4,252,755.00 美元。交易完成后，该董事直接持有该公司 2,352 股股票，价值约为 1,538,843.04 美元。这代表了他们持股的 73.43% 的减少。该交易的 SEC 文件提供了更多信息。当前 7.02% 的股票由内部人士持有。</p>
</div><h2>About Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于再生元制药</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.</p>
<div class="lb-trans"><p>再生元制药公司（Regeneron Pharmaceuticals, Inc.）纳斯达克代码：REGN，是一家成立于 1988 年，总部位于纽约塔里敦的美国生物技术公司。该公司专注于发现、开发、生产和商业化用于治疗严重医疗状况的药物。公司结合实验室研究、临床开发和内部生产，推进多个治疗领域的生物治疗管线。</p>
</div><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p>
<div class="lb-trans"><p>再生元以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比再生元制药更好的股票</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的水晶金属性能超过硅达 100 倍</li>
<li>来自奇怪的新 “AI 燃料” 的 33000% 繁荣？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding REGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 REGN 感兴趣的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取再生元制药公司（NASDAQ:REGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Exchange Traded Concepts LLC 购买了 1,369 股再生元制药公司（股票代码：$REGN）的股票